Mangoceuticals, Inc. Schedules Special Stockholder Meeting for March 25, 2024

TL;DR

<b>Mangoceuticals, Inc. will hold a special stockholder meeting on March 25, 2024, to vote on important proposals.</b>

AI Summary

MANGOCEUTICALS, INC. (MGRX) filed a Proxy Statement (DEF 14A) with the SEC on March 1, 2024. Mangoceuticals, Inc. is holding a special meeting of stockholders on Monday, March 25, 2024, at 12 p.m. Central Time. The meeting will take place at 15110 Dallas Parkway, Suite 600, Dallas, Texas 75248. Stockholders can access the Notice of Special Meeting and Proxy Statement online at www.cleartrustonline.com/mgrx. Copies of the proxy statement can be requested by contacting the company's main office at (214) 242-9619. The proxy materials were first distributed to stockholders on March 1, 2024.

Why It Matters

For investors and stakeholders tracking MANGOCEUTICALS, INC., this filing contains several important signals. This meeting is crucial for stockholders to participate in corporate governance by voting on proposals presented by the Board of Directors. The company strongly encourages all stockholders, whether attending in person or not, to submit their proxy to ensure their shares are represented and their vote is counted.

Risk Assessment

Risk Level: low — MANGOCEUTICALS, INC. shows low risk based on this filing. The filing is a routine proxy statement for a special meeting, with no immediate financial or operational disclosures that would indicate high risk.

Analyst Insight

Stockholders should review the proxy statement carefully and vote their shares on the proposals presented by the Board of Directors.

Key Numbers

• March 25, 2024 — Special Meeting Date (Date of the special meeting of stockholders.)
• 12 p.m. Central Time — Special Meeting Time (Time of the special meeting.)
• March 1, 2024 — First Mailing Date (Date proxy materials were first sent to stockholders.)

Key Players & Entities

• Mangoceuticals, Inc. (company) — Registrant and filer of the proxy statement.
• March 25, 2024 (date) — Date of the special meeting of stockholders.
• 12 p.m. Central Time (time) — Time of the special meeting.
• 15110 Dallas Parkway, Suite 600, Dallas, Texas 75248 (location) — Physical location of the special meeting.
• www.cleartrustonline.com/mgrx (url) — Website where proxy materials are available.
• (214) 242-9619 (phone) — Contact number to request proxy statement copies.
• March 1, 2024 (date) — Date proxy materials were first sent to stockholders.

FAQ

Industry Context

Mangoceuticals, Inc. operates in the health and allied services sector, focusing on products or services related to pharmaceuticals or wellness.

Regulatory Implications

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.

What Investors Should Do

1. Review the full proxy statement for details on proposals to be voted on.
2. Submit proxy votes by mail, fax, internet, or telephone as instructed.
3. Contact the company at (214) 242-9619 if you have not received proxy materials or have questions.

Key Dates

• 2024-03-25: Special Meeting of Stockholders — Key date for stockholders to vote on company proposals.
• 2024-03-01: First Mailing of Proxy Materials — Indicates when stockholders received the official notice and proxy statement.

Year-Over-Year Comparison

This is a definitive proxy statement (DEF 14A) filed on March 1, 2024, for a special meeting, indicating a specific event rather than routine quarterly or annual reporting.

Key Financial Figures

• $0.0001 — g shares of our common stock, par value $0.0001 per share, by a ratio of between one-fo
• $10,000 — a fee which we do not expect to exceed $10,000 plus costs and expenses. In addition, C

Filing Documents

• formdef14a.htm (DEF 14A) — 480KB
• formdef14a_001.jpg (GRAPHIC) — 4KB
• appendixa_001.jpg (GRAPHIC) — 3KB
• proxy_001.jpg (GRAPHIC) — 491KB
• proxy_002.jpg (GRAPHIC) — 350KB
• 0001493152-24-008415.txt (&nbsp;) — 1649KB

FORWARD-LOOKING STATEMENTS AND WEBSITE LINKS

FORWARD-LOOKING STATEMENTS AND WEBSITE LINKS 7 REFERENCES TO ADDITIONAL INFORMATION 7 VOTING RIGHTS AND PRINCIPAL STOCKHOLDERS 8

Security Ownership of Management and Certain Beneficial Owners and Management

Security Ownership of Management and Certain Beneficial Owners and Management 8 Change of Control 9 PROPOSAL 1 AMENDMENT TO CERTIFICATE OF FORMATION, AS AMENDED, TO EFFECT A REVERSE STOCK SPLIT 9 General 9 Purpose 10 Accounting Matters 11 Risks of the Proposed Reverse Stock Split 11 Principal Effects of the Reverse Stock Split 13 Fractional Shares 16 Determination of the Reverse Stock Split Ratio 17 Potential Consequences if the Reverse Split Proposal is Not Approved 17 Effective Date and Time of the Reverse Stock Split 17 No Dissenters&rsquo; Rights 18 Certain United States Federal Income Tax Consequences 18 Exchange of Stock Certificates 20 Book-Entry Shares 21 Interests of Directors and Executive Officers 21 Vote Required 21 Board Recommendation 21 PROPOSAL 2 ADOPTION OF THE FIRST AMENDMENT TO THE Mangoceuticals, Inc. 2022 22 EQUITY INCENTIVE PLAN 22 General 22 Background and Purpose of the Amended Plan 22 Current Overview of Outstanding Equity Information 22 Summary of the Material Terms of the Amended Plan 23 Vote Required 31 Board Recommendation 31 General 32 Vote Required 32 Board Recommendation 32 OTHER MATTERS 33 Additional Filings 33 Other Matters to be Presented at the Special Meeting 33 Interest of Certain Persons in or Opposition to Matters to Be Acted Upon: 33 Company Contact Information 33 WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION OF INFORMATION BY REFERENCE 33 Appendix A &ndash; Form of Certificate of Amendment of Certificate of Formation of Mangoceuticals, Inc. A-1 Appendix B &ndash; First Amendment to Mangoceuticals, Inc. 2022 Equity Incentive Plan B-1 iii PROXY FOR SPECIAL MEETING OF STOCKHOLDERS GENERAL INFORMATION Mangoceuticals, Inc. (&ldquo; we, &rdquo; &ldquo; us &rdquo;, &ldquo; our &rdquo; or the &ldquo; Company &rdquo;) has made these materials available to you or delivered printed versions of these ma

View Full Filing

View this DEF 14A filing on SEC EDGAR